Moderna reports Q1 revenue surge driven by international COVID vaccine sales despite larger net loss

Moderna posted first‑quarter revenue of $389 million, more than triple the same period a year earlier, primarily from overseas COVID‑19 vaccine sales.

The company recorded a net loss of $1.3 billion, about $1 billion larger than a year ago, reflecting charges tied to a litigation settlement with Arbutus Biopharma and Genevant Sciences.

Shares briefly rose up to 7% before slipping back, leaving the stock near $45, a level not seen since late 2024, as cost‑cutting measures and growing interest in Moderna’s cancer pipeline support the ongoing turnaround that has nearly doubled its market value since late last year.